5001-45-6 Usage
Description
(+),(-)-A-2,4,5,7-TETRANITRO-9-FLUORENYLIDENEAMINOOXYPROPIONIC ACID is a complex chemical compound characterized by its nitro functional group and a highly reactive nature. (+),(-)-A-2,4,5,7-TETRANITRO-9-FLUORENYLIDENEAMINOOXYPROPIONIC ACID is known for its potential to act as a sensitizing agent in the field of explosives, where it plays a crucial role in reducing the activation energy necessary for explosive reactions.
Uses
Used in Explosive Materials Industry:
(+),(-)-A-2,4,5,7-TETRANITRO-9-FLUORENYLIDENEAMINOOXYPROPIONIC ACID is used as a sensitizing agent for enhancing the reactivity of explosive materials. Its incorporation into these materials serves to lower the energy threshold required for detonation, making the explosives more sensitive and responsive to initiating stimuli.
Due to its highly reactive and potentially explosive nature, (+),(-)-A-2,4,5,7-TETRANITRO-9-FLUORENYLIDENEAMINOOXYPROPIONIC ACID must be handled and stored with extreme care and caution to prevent accidental detonation or decomposition. This requirement underscores the need for stringent safety protocols in industries where this compound is utilized.
Check Digit Verification of cas no
The CAS Registry Mumber 5001-45-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,0,0 and 1 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 5001-45:
(6*5)+(5*0)+(4*0)+(3*1)+(2*4)+(1*5)=46
46 % 10 = 6
So 5001-45-6 is a valid CAS Registry Number.
5001-45-6Relevant articles and documents
Camptothecin derivatives as chemoradiosensitizing agents
-
Page/Page column 35, (2008/06/13)
Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.
